Categories

Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

US$ 2500

“The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

07-22 2015   Pages: 37

GALAPAGOS – Hiccups due to EULAR ’13 – GLPG0634 data manageable, Maturing Pipeline + Partnerships of Novel Targets opportunity remains!

US$ 140

Galapagos (GLPG) presented detailed PhIIa data at EULAR ’13 (Abstract # THU0229) of GLPG0634 (PhII, a selective JAK1 inhibitor, partnered with Abbott for RA) at 4 weeks which differed from the previously presented PoC 4-week data at ACR ’12 – 2489 (Table 1).

07-22 2015   Pages: 5

Incyte – Label Expansion + Upcoming Milestones Sufficient Reason to Remain Invested for Long Term!

US$ 140

Recent positives news flow reaffirms our confidence in further growth of launched product JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET, partnered with Novartis for Ex-US rights) and Incyte’s (INCY) maturing pipeline. PhII data of oral RA drug Barcitinib (PhIII) partnered with Lilly looks cleaner than PFE’s launched oral RA drug (Xeljanz, tofacitinib, JAK1/3 inhibitor) with efficacy sustainable at 52 weeks.

07-22 2015   Pages: 9

Acorda Therapeutics – Pipeline and Label Expansion of AMPYRA- Drivers of Growth

US$ 140

Stable sales from marketed products, maturing pipeline and focus on targeting unmet needs in CNS diseases- Acorda (ACOR) has not disappointed its investors (YoY gain of 49.68%). Top-line data from two separate proof-of-concept trials of AMPYRA in treating post-stroke deficits and cerebral palsy (CP) showed improved walking in people with post-stroke deficits and was statistically significant for the timed 25 ft walking measure.

07-22 2015   Pages: 3

MorphoSys – MOR103 – Partnering is Just the Beginning of a New Phase of Growth

US$ 140

Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are future drivers of Morphosys (MOR). After selling its services division (AbD Serotec) last year MOR is poised to evolve into a successful biotech company on the strength of its innovative platforms to develop biologics.

07-22 2015   Pages: 5

ASCO ‘13 – Promise of Novel Targets/Technologies to Unfold At ASCO 2013

US$ 140

New cancer therapies are being developed through targeted approaches that can accelerate development of more efficacious, personalized treatments.

07-22 2015   Pages: 12

Infinity Pharma – ASCO ‘13 to Reinstate Faith in IPI-145!

US$ 140

Infinity (INFI) shares down on concerns that IPI-145 (PI3K-delta, gamma isoform inhibitor, PhI/II, hematological malignancies, inflammation) may not be differentiated enough from Gilead’s idelalisib (GS-1101, PI3K delta, PhIII) or other new compounds in the pipeline.

07-22 2015   Pages: 4

Halozyme – HyQvia Approval in EU and Upcoming milestones = Upside

US$ 140

Approval of HyQvia (L, 10% Gammagard liquid + rHuPH20, partnered with Baxter for primary immunodeficiencies, PI) in Europe increases the probability of approval of Herceptin SC and MabThera SC in 2Q13 and YE13 respectively. Clarity on the timelines of approval of HyQvia SC in US is expected this quarter.

07-22 2015   Pages: 4

Pharmacyclics – Ibrutinib: A Game Changer – 3 Breakthrough Therapy Designations + More Data @ ASCO/EHA ‘13

US$ 140

ASCO ‘13 abstracts highlight Ibrutinib (PCI-32765, PhIII, BTK inhibitor, partnered with JNJ, PhIII, CLL/SLL/PLL, MCL; PhII, DLBCL, MM, FL) leads in the new treatment options in development for hematological malignancies. Ibrutinib, a small molecule is being studied as a monotherapy and has shown robust efficacy and safety vs. GILD’s PI3K inhibitor, Idelalisib (PhIII, CLL; PhII, NHL).

07-22 2015   Pages: 10

Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies

US$ 2500

There are more than 1400 sustained or controlled release drugs approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of the overall international pharmaceutical market. Utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.

07-22 2015   Pages: 123
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample